Vericel Corporation (NASDAQ:VCEL) Files An 8-K Results of Operations and Financial Condition

Vericel Corporation (NASDAQ:VCEL) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02. Results of Operations and Financial Condition

On March 10, 2017, the Registrant issued a press release, a copy
of which is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
The information in this Report on Form 8-K and Exhibit 99.1
attached hereto is intended to be furnished and shall not be
deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
Exhibit No.
Description
99.1
Press Release dated March 10, 2017.


About Vericel Corporation (NASDAQ:VCEL)

Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Vericel Corporation (NASDAQ:VCEL) Recent Trading Information

Vericel Corporation (NASDAQ:VCEL) closed its last trading session 00.00 at 2.90 with 316,226 shares trading hands.

An ad to help with our costs